Non-small cell lung cancer

News

Survival data back Tagrisso's role in first-line lung cancer

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

News

Nuvalent chases after Nuvation in ROS1 lung cancer

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

News

AZ, Daiichi get Datroway nod in lung cancer on second try

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

News

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.

News

Summit shrugs off survival miss with its VEGF bispecific

Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.

Survival data back Tagrisso's role in first-line lung cancer

Dizal set to bring lung cancer drug Zegfrovy to US

Nuvalent chases after Nuvation in ROS1 lung cancer

AZ, Daiichi get Datroway nod in lung cancer on second try

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Summit shrugs off survival miss with its VEGF bispecific

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Non-small cell lung cancer

Editor's Picks